arrow
R

R. Charles Coombes

imperial college london
H指数:115
被引数:5.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer

CDK7抑制剂Samuraciclib联合氟维司群治疗晚期HR+/HER2−乳腺癌的随机对照试验

2026-10-050
OAAI
Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing

通过DEPArray辅助的固定石蜡包埋组织中纯癌和基质细胞群的分选,结合浅层全基因组测序,鉴定可操作靶点

2025-10-270
OAAI
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (vol 14, 4444, 2023

CDK7抑制剂samuraciclib I期研究中,晚期乳腺癌患者的剂量递增和扩展队列(vol 14, 4444, 2023)

2025-03-060
OA
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer
2024-10-020
PRE
Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study (Jan, 10.1007/s10549-023-07229-y, 2024)

一种新的基于光谱的激素受体阳性乳腺癌辅助治疗决策工具的性能: 一项验证研究 (1月,10.1007/s10549-023-07229-y,2024)

2024-05-050
OAAI
Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study

一种新的基于光谱的激素受体阳性乳腺癌辅助治疗决策工具的性能: 一项验证研究

2024-01-203
OAAI
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
2023-07-2418
OAAI
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
2022-10-0514
OAAI
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)
2022-02-152
PRE